Triterpenoid Therapeutics
A biotechnology company developing brain‑penetrant synthetic triterpenoid small molecules that simultaneously inhibit inflammatory signaling (NLRP3 inflammasome) and modulate the Integrated Stress Response (ISR). The organization focuses on preclinical development of orally bioavailable compounds with demonstrated blood–brain barrier penetration and activity in neurodegenerative and brain cancer models, and maintains a pipeline of fluorinated analogs and patent filings.
Industries
N/A
Products
Lead oral brain‑penetrant triterpenoid (lead compound)
A fourth‑generation synthetic triterpenoid small molecule designed for oral delivery and CNS penetration with preclinical evidence of high potency, NLRP3 inhibition, ISR modulation, neuroprotection, and anti‑tumor activity in glioblastoma models.
Pipeline of fluorinated triterpenoid analogs
A series of patent‑pending fluorinated analogs intended to enhance brain penetration, selectivity, and safety while retaining oral bioavailability.
Lead oral brain‑penetrant triterpenoid (lead compound)
A fourth‑generation synthetic triterpenoid small molecule designed for oral delivery and CNS penetration with preclinical evidence of high potency, NLRP3 inhibition, ISR modulation, neuroprotection, and anti‑tumor activity in glioblastoma models.
Pipeline of fluorinated triterpenoid analogs
A series of patent‑pending fluorinated analogs intended to enhance brain penetration, selectivity, and safety while retaining oral bioavailability.
Expertise Areas
- Small‑molecule medicinal chemistry
- Brain‑penetrant drug development
- NLRP3 inflammasome biology
- Integrated Stress Response (ISR) modulation
Key Technologies
- Synthetic triterpenoid scaffold chemistry
- Blood–brain barrier penetration assessment
- NLRP3 inflammasome inhibition assays
- Integrated Stress Response pathway assays